A phase 2 proof of concept study of GNbAC1 in the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP).
Phase of Trial: Phase II
Latest Information Update: 27 Feb 2018
Price : $35 *
At a glance
- Drugs Temelimab (Primary)
- Indications Chronic inflammatory demyelinating polyradiculoneuropathy
- Focus Proof of concept; Therapeutic Use
- 27 Feb 2018 New trial record
- 22 Feb 2018 According to a GeNeuro media release, company will start discussing with the FDA regarding the design of this study.